Relationship between serum omentin-1 levels and nascent metabolic syndrome in Caucasian patients with obesity

  • 0Centro de Investigación en Endocrinología y Nutrición Clínica (IENVA). Facultad de Medicina. Servicio de Endocrinología y Nutrición. Hospital Clínico Universitario. Universidad de Valladolid.

|

|

Summary

This summary is machine-generated.

Omentin-1 levels are lower in individuals with metabolic syndrome (MS). Lower omentin-1 correlates with increased adiposity, insulin resistance, and triglycerides, suggesting its role in MS development.

Area Of Science

  • Endocrinology
  • Metabolic Research
  • Obesity Studies

Background

  • Metabolic syndrome (MS) is a growing health concern.
  • Omentin-1, an adipokine, is implicated in metabolic regulation.
  • The relationship between omentin-1 and early-stage MS requires further elucidation.

Purpose Of The Study

  • To investigate the association between serum omentin-1 levels and nascent metabolic syndrome in obese subjects.
  • To identify predictors of metabolic syndrome in this population.

Main Methods

  • A cross-sectional study involving 606 obese individuals.
  • Assessment of adiposity, blood pressure, glucose metabolism (including HOMA-IR and TyG index), lipid profile, C-reactive protein, and serum omentin-1.
  • Statistical analysis to determine correlations and predictors of MS.

Main Results

  • Subjects without MS exhibited significantly higher omentin-1 levels compared to those with MS.
  • Omentin-1 showed inverse correlations with adiposity parameters, glucose, insulin, HOMA-IR, TyG index, and triglycerides.
  • Omentin-1 demonstrated a positive correlation with HDL-cholesterol.
  • Obesity (BMI), insulin resistance (HOMA-IR), and serum omentin-1 were identified as independent predictors of MS.
  • A serum omentin-1 cut-off of 372.45 ng/ml was determined for MS prediction.

Conclusions

  • Obese Caucasian individuals with nascent MS present with reduced serum omentin-1 levels.
  • Serum omentin-1 levels are inversely associated with key metabolic syndrome components, including insulin resistance and triglycerides.
  • Omentin-1 may serve as a potential biomarker for early detection of metabolic syndrome in obese populations.